EyeGate Pharmaceuticals, Inc. Email Format
PharmaceuticalsMassachusetts, United States11-50 Employees
EyeGate Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on eye diseases, based in Waltham, Massachusetts. It pursues two proprietary platform approaches to develop therapies for the eye, including a gel-form formulation derived from a modified hyaluronic acid designed to hydrate and support healing on the ocular surface. The leading product from the first platform, EyeGate Ocular Bandage Gel, is a topically applied eye drop intended to protect and accelerate healing of large corneal defects after PRK surgery. The second platform centers on EGP-437, a reformulated corticosteroid delivered through the EyeGate II Delivery System to treat inflammatory conditions of the eye, including post-surgical inflammation and pain and uveitis, with the system having supported more than 2,400 treatments in clinical trials. The company has entered into exclusive worldwide licensing agreements with Valeant subsidiaries to commercialize and manufacture EGP-437 for those indications in the eye.